The transfer of defi ned TCR genes into human T cells appears to be a promising new strategy for redirecting T cells against cancer cells. In this approach, TCR genes with specifi city for a known tumor antigen are introduced into the T cells of a patient whose tumor expresses the antigen and shares the MHC-restricting allele, and the modifi ed cells are then expanded in vitro and infused back into the patient ( 1 ). A recent clinical study demonstrated the feasibility of this strategy ( 2 ) , but the observed clinical effi cacy was limited, in part because of the low avidity of the transduced T cells. Thus, a major challenge is to defi ne means to improve the avidity of T cells transduced with a potentially tumor-reactive TCR, particularly in the context of the generally low affi nity of available tumor-reactive TCRs. Besides selecting tumor-reactive TCRs with the highest identifiable affi nity ( 3 -5 ) , strategies to increase TCR affi nity before transduction ( 6, 7 ) or the (functional) avidity of the resulting TCR-transduced T cells ( 8, 9 ) should be explored. In this context, " affi nity " will be defi ned as the strength of binding of one receptor with its ligand, " avidity " as the strength of binding between multiple demonstrate with several TCRs recognizing diff erent antigens that the removal by point mutation of defi ned N -glycosylation motifs in the constant domains of TCR chains can increase the functional avidity of T cells transduced with these TCRs, and that this translates into enhanced recognition of tumor cells. As these N -glycosylation sites in the constant domain are conserved in all TCRs, this strategy should be easily translated to TCRs with any specifi city.
RESULTS

Selective N -deglycosylation of TCR chains increases functional avidity of TCR-transduced 58 ␣ ؊ ␤ ؊ cells as compared with 58 ␣ ؊ ␤ ؊ cells transduced with WT TCR chains
To determine if reducing N -glycosylation of TCR chains can aff ect functional T cell avidity, we fi rst analyzed the ␣ and ␤ chain sequence of two mouse ( 3, 4 ) and one human ( 9 ) TCRs for characteristic N -glycosylation sites ( N-X-S/T; see Materials and methods; Fig. 1 ), as located according to the ImMunoGeneTics (IMGT) nomenclature ( 20 ) . N -glycosylation sites were detected in the variable domain of all analyzed ␣ chains but not in the variable domain of any of the tested ␤ chains ( Fig. 1 ) . The mouse constant ␣ chain harbors two N -glycosylation sites (c-90 and c-113). Although the location of these N -glycosylation sites are conserved in the human constant ␣ chain (c-90 and c-109), the threonine of the motifs is replaced by an equally acceptable serine residue. The human constant ␣ chain also has an additional N -glycosylation site at position c-36. The mouse constant ␤ chain has three N -glycosylation sites, whereas the human constant ␤ chain harbors only a single receptors and their ligands, and " functional avidity " as the sensitivity of a T cell response to a target cell expressing the relevant peptide -MHCs (pMHCs).
Diff erent strategies have been examined to increase the affi nity of TCRs used for transduction. TCR phage ( 7 ) and yeast ( 6 ) displays have been used as formats to express TCR chains and to then generate mutants that can be screened ex vivo for increased affi nity. With these approaches, a library of TCR chains can be created generally after random mutation of defi ned regions, such as CDR3, known to be important in recognition; the library expressed on the surface of the phage or yeast; the expressed mutated TCR chains screened by tetramer binding for increased affi nity; and the cDNA encoding the highest affi nity chains extracted, characterized, and subsequently used for transduction. Consequently, these display strategies can be very eff ective but are cumbersome and must be individualized for each TCR. Furthermore, not every TCR can be successfully expressed and modifi ed by these technically challenging display strategies in nonmammalian systems (unpublished data), emphasizing the need for alternative techniques to increase TCR affi nity or functional avidity of a T cell.
The functional avidity of a T cell, as refl ected by responsiveness to antigen, is modulated by T cell surface O -or Nglycosylation ( 10, 11 ) , with increased glycosylation of T cell surface proteins associated with an increased activation threshold. This has been reported to contribute to the higher activation thresholds of tolerant T cells ( 12 ) , aged as compared with young T cells ( 13, 14 ) , and naive as compared with activated or memory T cells ( 15, 16 ) , and molecules such as CD43 and CD45 have been reported to be directly involved. The reciprocal event, decreased glycosylation of surface proteins, has been reported to result in a decreased activation threshold. For example, decreased glycosylation of CD8 during thymic development is associated with increased affi nity of CD8 with pMHC and, subsequently, improved signaling ( 17, 18 ) . Moreover, a general defi ciency in ␤ 1,6 N -acetylglucosaminyltransferase V (Mgat5) in mice, an enzyme in the N -glycosylation pathway, mediates increased T cell activity in vitro and results in autoimmune disease in vivo ( 19 ) . Although defi ciency of this N -glycosylation pathway enzyme in mice resulted in reduced N -glycosylation of all proteins, the reduced N -glycosylation of the TCRs appeared to specifically result in increased TCR mobility at the cell surface, enhanced recruitment to the synapse (TCR clustering), improved TCR engagement/down-modulation, and, consequently, enhanced functional avidity of the T cells. To test if selectively reducing N -glycosylation of TCR chains might achieve some of these eff ects, N -glycosylation of cloned TCR genes was prevented by sequentially deleting before expression N -glycosylation motifs (asparagine -any amino acidserine/threonine[N-X-S/T]) in the ␣ and/or ␤ chain by changing N to glutamine (Q) by site-directed mutagenesis. The WT and/or modifi ed TCR chains were expressed in hybridomas or human T cells, and TCR expression, tetramer staining, and functional avidity of the T cells was assessed. We To assess functional avidity of transduced 58 ␣ Ϫ ␤ Ϫ cells, IL-2 secretion was assessed in response to K562-A2 cells pulsed with titrated amounts of p53 [264] [265] [266] [267] [268] [269] [270] [271] [272] peptide. The peptide concentration required to reach half-maximal IL-2 secretion (EC50) was calculated and transformed to log scale (log EC50 ). 58 ␣ Ϫ ␤ Ϫ cells expressing v ␣ 3 WT /v ␤ 3 WT TCR had a log EC50 of -6 ± 0.1 M, and 58 ␣ Ϫ ␤ Ϫ cells expressing v ␣ 3 c-90 /v ␤ 3 WT had N -glycosylation site at position c-85.6, which corresponds to the mouse N -glycosylation site at position c-84.5.
The potential contribution of distinct glycosylation sites within TCR chains to modulating activation after antigen encounter was assessed by modifying WT mouse v ␣ 3 WT and v ␤ 3 WT TCR chains isolated from a mouse CD8 + T cell clone that had been derived from a transgenic mouse expressing human HLA-A*0201 (HLA-A2) and was specifi c for the HLA-A2 -restricted p53-derived epitope p53 [264] [265] [266] [267] [268] [269] [270] [271] [272] ( 4 ) . Furthermore, this TCR is CD8 independent, thus allowing analysis of the role of CD8 in the function of a deglycosylated TCR chain. N -glycosylation of TCR chains was prevented at specifi c sites (TCR chains with To assess tetramer binding of the diff erent TCR chains, 58 ␣ Ϫ ␤ Ϫ cells mock transduced or transduced with WT only or combinations of WT and ⌬ TCR chains were incubated with the p53 264-272 tetramer at 4 ° C for analysis by fl ow cytometry of TCR -pMHC interactions in the absence of temperature-dependent mechanisms such as increased membrane fl uidity, diff usion rates, and conformational changes. Mocktransduced 58 ␣ Ϫ ␤ Ϫ cells did not bind the p53 264-272 tetramer. In contrast, ‫ف‬ 70% of the 58 ␣ Ϫ ␤ Ϫ cells transduced with any of the pairs of TCR chains bound the p53 264-272 tetramer, and the MFI of the tetramer-positive populations was ‫ف‬ 40 -70 for 58 ␣ Ϫ ␤ Ϫ cells expressing WT and ⌬ TCR chains ( Fig. 2 B ; Fig. 3 A ) . Expression of the v ␣ 3 chain could not be monitored directly because of the lack of a commercially available antibody. However, mouse TCR chains are preferentially expressed with each other and not with human endogenous TCR chains ( 8, 21, 22 ) , and measuring the introduced ␤ chain should be a good general indication of expression of the introduced mouse ␣ chain in these polyclonal populations. Moreover, v ␣ 3 expression was indirectly assessed by isolating mRNA from the transduced T cells, reverse transcribing the mRNA into cDNA, analyzing the product with PCR primers detecting the unique CDR3 domain of the TCR ␣ chain, and normalizing to the number of ␤ -actin copies. Equivalent amounts (1:1 ratio) of v ␣ 3 WT and v ␣ 3 c-90 RNA levels were detected in cells previously selected based on equivalent v ␤ 3 surface expression.
To assess tetramer binding of WT and ⌬ TCR chain heterodimers in human T cells in the absence of the CD8 coreceptor, transduced CD4 + T cells were incubated with though the presence of the coreceptor CD8 increased the functional avidity of this class I -restricted T cell response, recruitment of T cells and production of cytokine per cell was still further increased in the presence of ⌬ TCR as compared with WT TCR chains.
To assess the impact of a ⌬ TCR in transduced T cells on recognition of cells expressing more physiological levels of antigen, mock-transduced T cells and v ␣ 3 c-90 /v ␤ 3 WT or v ␣ 3 WT / v ␤ 3 WT TCR -transduced CD8 + T cells were tested for recognition of the HLA-A2 -positive p53-negative cell line Soas2, and the HLA-A2 -positive p53-overexpressing tumor cell lines MDAMB231, SW480, and MZ1851RC in a 5-h 51 Cr-release assay at a low eff ector/target ratio of 0.3:1 ( Fig. 4 B ) . No T cell lines lysed the negative control Saos2, and mock-transduced T cells did not lyse any tumor targets. In contrast, the concentration inducing half-maximal IFN-␥ secretion was determined and transformed to log EC50 . The v ␣ 3 WT /v ␤ 3 WTtransduced T cells had a log EC50 for IFN-␥ secretion of Ϫ 7.5 ± 0.1 M ( Fig. 3 C ) , whereas the V ␣ 3 c-90 /v ␤ 3 WT TCR -transduced CD4 + T cells had a log EC50 of Ϫ 7.9 ± 0.1 M ( Fig. 3 C ) . Again, ⌬ log EC50 (0.4) was calculated from two independent assays (P = 0.02). ( Fig. 3 D ) . 51 Cr-release assay ( t test: *, P < 0.05; **, P < 0.01; error bars are SEM). All assays were performed in duplicates. All data are representative of at least two independent experiments. v ␤ 3 WT TCR, 100 nM; and CD4 + v ␣ 3 WT /v ␤ 3 WT , ≥ 414 nM), consistent with the higher functional avidity previously observed for ⌬ TCR as compared with WT TCR -transduced T cells.
TCR internalization of WT and ⌬ TCR in transduced T cells after antigen-specifi c stimulation
Globally reduced N -glycosylation in T cells has been suggested to improve T cell signaling by improving mobility of the TCR on the cell membrane, thereby enhancing TCR recruitment to the synapse and increasing the frequency of TCR -pMHC interaction, which results in augmented signaling and greater TCR internalization/endocytosis ( 19 ) . We examined whether depletion of a single N -glycosylation v ␣ 3 c-90 /v ␤ 3 WT and v ␣ 3 WT /v ␤ 3 WT TCR -transduced CD8 + T cells lysed all of the p53-overexpressing cell lines. Greater lysis of tumor targets was achieved with T cells transduced with the ⌬ TCR chains, which was signifi cantly diff erent by a t test from lysis by T cells transduced with WT TCR chains ( ⌬ TCR/WT TCR: MZ1851RC, 23%/11%, P < 0.01; MD-AMB231, 26%/14%, P < 0.01; SW480, 55%/30%, P < 0.05). Thus, substituting v ␣ 3 WT with v ␣ 3 c-90 improved lysis of cells that endogenously process and present antigen.
Tetramer binding of T cells transduced with WT and partially deglycosylated TCR chains
Functional avidity of TCR-transduced T cells has been reported to correlate with tetramer binding ( 9 ) . However, our results with transduced 58 ␣ Ϫ ␤ Ϫ , CD4 + , and CD8 + T cells indicated an increase in functional avidity for v ␣ 3 c-90 /v ␤ 3 WTcompared with v ␣ 3 WT /v ␤ 3 WT -transduced cells despite apparently equivalent tetramer binding ( Figs. 2 -4 ). Because these tetramer-binding experiments were performed at 4 ° C, which precludes temperature-dependent events such as increased membrane fl uidity and conformational changes, tetramer binding was reanalyzed at 37 ° C to permit temperature-dependent changes that might infl uence TCRpMHC binding ( 23 -25 ) ( Table I and Fig. 5, A and B ) . Thus, in contrast to tetramer binding at 4 ° C, analysis at 37 ° C revealed that the v ␣ 3 c-90 /v ␤ 3 WT TCR -transduced CD4 + T cells bound tetramer with a lower K D than WT receptors, whereas CD8 + T cells transduced with the v ␣ 3 c-90 /v ␤ 3 WT TCR appeared to achieve only a slightly improved K D compared with WT TCR -transduced T cells. To more precisely analyze the K D changes in CD4 + and CD8 + T cells, the K D was reanalyzed by determining tetramer association and dissociation rather than the previous Scatchard analysis, which permitted determining the association (k on ) and dissociation (k off ) rates. As described in Materials and methods, k ob was assessed during tetramer association; t 1/2 and k off were assessed during tetramer dissociation; and k on and K D were then derived ( Table I and Fig. 5, C -F motif from a TCR chain can also facilitate this process, and used TCR internalization as the measurable objective endpoint. Therefore, v ␣ 3 c-90 /v ␤ 3 WT or v ␣ 3 WT /v ␤ 3 WT TCRtransduced CD4 + T cells were co-cultured with T2 cells pulsed with 10 Ϫ 6 or 10 Ϫ 8 M of p53 264-272 peptide, and surface expression of the introduced TCR ␤ chain was assessed before and at 2, 4, and 6 h after stimulation by fl ow cytometry. For the comparisons, surface expression of the introduced mouse TCR ␤ chain before antigen encounter was set as 100%, no detectable surface expression of mouse TCR ␤ chain was set as 0%, and the surface expression after antigen encounter was calculated as the percentage of total TCR ␤ chain surface expression before antigen encounter. A maximal 80% down-regulation of the introduced mouse TCR ␤ chain was observed at 10 Ϫ 6 M, and 50% TCR ␤ chain down-regulation was observed at 10 Ϫ 8 M for both v ␣ 3 c-90 / v ␤ 3 WT and v ␣ 3 WT /v ␤ 3 WT TCR -transduced CD4 + T cells (Fig. S3 , available at http://www.jem.org/cgi/content/full/ ity, with 20.6% of cells producing cytokine as compared with 6.1% for WT TCR -transduced T cells ( Fig. 6 B ) . . Because of the loss of tetramer binding at 37 ° C as compared with 0 ° C with these human WT1-specifi c TCR chains, the K D could not be calculated at 37 ° C ( Table I ) ( 33 ) . NOD/SCID mice were immunized only with 10 μ g WT1 126-134 peptide. 6 h later, mice received a single subcutaneous injection of 6 × 10 5 IU of rhIL-2 resuspended in incomplete Freund ' s adjuvant ( 34 ) to enhance in vivo activation, survival, and expansion of the transferred cells. Mice were monitored for overall survival, weight loss, and persistence of the transferred transduced T cells. CD8 + T cells transduced with WT and mutated TCR chains were detected by fl ow cytometry in the peripheral blood of HLA-A2 × NOD/SCID mice immunized with theWT1 126-134 peptide 2 wk after cell transfer ( n = 8; mean v ␣ 21 WT /v ␤ 21 WT , 1%; mean v ␣ 21 c-36 /v ␤ 21 WT , 1.3%), whereas < 0.5% of T cells (below the detection threshold) were detectable at 2 wk in HLA-A2 × NOD/SCID mice immunized with FluM1 58-66 or NOD/SCID control mice immunized with the WT1 peptide but that lack the HLA-A2 allele on host cells required to present the peptide ( n = 16), suggesting that antigen-specifi c proliferation of TCR-transduced T cells was induced by the peptide binding to recipient HLA-A2 in vivo (Fig. S4 A, available at http://www.jem.org/cgi/content/full/jem.20082487/DC1). In vivo proliferation of T cells after transfer and immunization was confi rmed by analyzing the dilution of CFSE in the transferred CD8 + T cells, which was not diluted on day 0 but became diluted after 2 wk in immunized mice expressing HLA-A2 (Fig. S4 B) . HLA-A2 × NOD/SCID mice in which proliferation of T cells with WT and mutated TCR chains was observed did not show any clinical sign of autoimmunity after 2 wk and remained healthy through a 4-wk observation period, suggesting no signifi cant toxicity mediated by the transferred T cells. After 4 wk, a time when transferred T cells could no longer be detected in the peripheral blood (unpublished data), the HLA-A2 × NOD/SCID mice were killed, organs (liver, spleen, and lung) were analyzed for histological signs of autoimmune injury, and bone marrow and spleen cells were analyzed by fl ow cytometry for the presence of CD8 + T cells. No infi ltrating human T cells were observed in the liver, lung, and bone marrow, and a normal histological structure of the liver, lung, and spleen mouse TCR chains, removal of the N -glycosylation motif in the ␣ chain at the interspecies conserved position c-90 did not improve functional avidity; however, depletion of the c-36 ( Fig. 6 B ) in the human ␣ chain showed an almost 3.4-fold increase in cytokine-secreting cells, indicating that removal of N -glycosylation sites in a human TCR chain can also improve the avidity of TCR-transduced T cells.
Gain of functional avidity mediated by N -deglycosylated TCR chains does not result in self-reactivity An undesirable eff ect of an increased avidity of a tumor antigen -specifi c T cell might be the recognition of normal tissue either by aberrant recognition of self-antigens ( 26 ) or recognition of the specifi cally targeted tumor antigen, such as WT1 ( 27 ) , p53 ( 28 ), or MDM2 ( 3 ), because of the physiological expression of the protein at lower levels in normal tissues. To test whether the increased avidity provided by deglycosylation of the human WT1 126-134 -, mouse p53 264-272 -, or mouse MDM2 81-88 -specifi c HLA-A2 -restricted TCR chains results in aberrant recognition of normal tissue, CD8 + T cells were mock transduced or transduced with the unmodifi ed TCR ␤ chain and the matched TCR ␣ chains depleted for the Nglycosylation motif at position c-36 (human) or c-90 (mouse), and were coincubated with a panel of normal HLA-A2 -positive cells (PBMCs, the fi broblast cell line MRC5, and CD34 + cells). As a positive control for the ability of these targets to be recognized, the target cells were also evaluated after pulsing with MDM2 81-88 at 10 Ϫ 6 M. All of these cell lines have previously been demonstrated not to be recognized by T cells transduced with the WT TCR chains used in this study, and recognition of the potential partial HLA mismatch by endogenous TCRs has previously been shown not to read out in this assay ( 3, 4, 9, 21 ) . As an additional positive control for the activity of TCR-transduced T cells, T2 cell targets were either not pulsed or pulsed with the relevant peptide (10 Ϫ 6 M). IFN-␥ secretion was measured by ELISPOT, and the reactivity of mock-and ⌬ TCR-transduced T cells was compared. ⌬ TCR-transduced T cells, similar to mock-transduced T cells, failed to recognize normal tissue targets ( Fig. 6 C ) , whereas these normal target cells pulsed with the MDM2 peptide induced IFN-␥ secretion by T cells transduced with this ⌬ TCR, suggesting that the normal target cells could be recognized but that the gain of functional avidity mediated by the N -deglycosylated TCR chains does not result in acquisition of self-reactivity against this set of normal cells.
With the modifi ed WT1-specifi c TCR, which was initially isolated from a normal human peripheral repertoire, it was also possible to analyze for potentially harmful in vivo reactivity with normal tissues in mice transgenic for human HLA-A2. The tissue distribution of expression of WT1 in normal tissues in mice is nearly identical to humans ( 29, 30 ) , the sequence of the human epitope recognized by the human WT1 126-134 -specifi c TCR is 100% identical in the mouse WT1 gene, the WT1 126-134 epitope has been shown to be effi ciently processed and presented by mouse cells ( 31, 32 ) , and transfer of WT1 126-134 -specifi c TCR-transduced human might be more readily achieved in the context of reduced Nglycosylated appendages on the TCR chains.
Enhanced tetramer staining of ⌬ TCR-compared with WT TCR -transduced T cells was observed in our studies at 37 ° C but not 4 ° C, indicating that temperature-dependent mechanisms are involved in the improved TCR -pMHC interaction. More detailed analysis revealed that tetramer dissociation was signifi cantly prolonged (up to approximately ninefold), whereas tetramer association was stable ( 36, 37 ) . Thus, the observed improved binding of pMHC complexes and functional avidity of transduced cells was a consequence of the TCR complexes remaining associated for longer periods after binding had occurred rather than a result of binding more quickly. Structural analysis of N -linked oligosaccharide in the constant domain ( Fig. 7 ) excluded that sugars linked to the constant TCR domains directly interact with a pMHC ligand. The slow off rate could therefore refl ect either greater clustering/multimerization or the assumption of a conformation after pMHC interaction that binds more avidly, and either event would be expected to be temperature dependent. Moreover, directly enhanced signaling through complexes formed by ⌬ TCR as compared with WT TCR chains is also suggested by the rather small improvement in tetramer binding at 37 ° C that was associated with the more impressive improvement in function.
The CD8 complex was not required for mediating the phenotype observed in ⌬ TCR-as compared with WT TCR -transduced T cells, as indicated by the improved functional avidity detected in CD4 + CD8 Ϫ T cells transduced with a TCR previously demonstrated to be capable of eliciting a CD8-independent signal ( 4 ). The lack of a requirement for CD8 is consistent with the structural analysis of the interaction site between CD8 and the TCR -pMHC, which is devoid of carbohydrates ( 38 ) . Moreover, in cells expressing the CD8 was observed. Transduced T cells were detected in the spleen of mice that received T cells with mutated TCR chains (v ␣ 21 c-36 /v ␤ 21 WT , 6.6%) but were below the detection threshold in recipients of T cells with WT TCR chains (v ␣ 21 WT /v ␤ 21 WT , < 0.5%; Fig. S4 C) . Thus, the increased avidity of T cells transduced with the ⌬ TCR for targets presenting WT1 resulted in a greater initial expansion in response to in vivo immunization and improved long-term persistence without evidence of toxicity to normal tissues.
DISCUSSION
We observed enhanced functional avidity as refl ected by cytokine secretion and lytic capacity after recognition of peptide-loaded targets, and improved recognition of tumor cells by T cells harboring ⌬ TCR. This was observed with both TCRs that exhibited a high affi nity in their WT form ( 3, 4 ) and a TCR that initially exhibited a more intermediate affi nity ( 9 ) . Reducing N -glycosylation of TCRs might be directly enhancing the interaction of TCRs with pMHCs and thereby increasing T cell activation. Two models have been proposed to explain how TCR -pMHC interactions result in T cell activation ( 24, 35 ) . The kinetic proofreading model proposes that the signaling machinery of T cells becomes activated once an activation threshold based on the time of occupancy of the TCR -CD3 cluster by the pMHC is reached, and the alternative model proposes that the agonist pMHC induces a specifi c conformational change in the TCR -CD3 that aff ects the quality of signals emanating from the ligated TCR -CD3 complex. In the former model, events such as TCR clustering/multimerization would be anticipated to contribute to the time of occupancy by increasing the number of concurrent interactions, and ⌬ TCR appendages might enhance T cell activation by facilitating TCR multimerization ( 24, 35 ) . In the latter model, the requisite conformational changes WT and modifi ed TCR chains, and TCR-transduced T cell lines. p53 264-272 -specifi c (v ␣ 3/v ␤ 3, mouse) ( 4 ), MDM2 81-88 -specifi c (v ␣ 13-D3/ v ␤ 6, mouse) ( 3 ), and WT1 126-134 -specifi c (v ␣ 21/v ␤ 21, human) ( 9 ) TCR chains are described in Fig. 1 A . N -glycosylation-sites ( N-X-S/T ) of ␣ and ␤ TCR chains are indicated in Fig. 1 (B and C) and are depicted according to the international IMGT system (available at http://imgt.cines.fr/) ( 20 ) . The prefi x " v " was added if the N -glycosylation site was located in the variable domain, and the prefi x " c " as added if it was located in the constant domain. To prevent N -glycosylation of TCR chains, the N in the N -glcyosylation site was changed to Q by site-directed mutagenesis (primers are shown in Table S1 , available at http://www.jem.org/cgi/content/full/jem.20082487/ DC1). Successful mutagenesis was confi rmed by sequencing. This modifi cation has been shown to prevent N -glycosylation of TCR chains ( 43 ) . The WT1 126-134 TCRs have been further modifi ed by introducing point mutations in the constant domains of both chains, as previously described to insert cysteines that can form a disulfi de bond and improve matched pairing and surface expression ( 9 ) . T cell transduction with modifi ed and WT TCR chains was performed as previously described ( 44 ) . In brief, Phoenix-Ampho cells were transfected using a transfection reagent (Fugene; Takara) with vectors containing the TCR chain (pBullet), gag-pol (pHIT60), and env (pCOLT-GALV) ( 3 ). Human PBMCs activated with 30ng/ml ␣ CD3 were transduced twice within 48 h in the presence of 40 -100 IU/ml IL-2 and 4 μ g/ml polybrene (Sigma-Aldrich), with a packaging cell supernatant containing retroviral vectors encoding for no protein (empty cassette), GFP (control), or ␣ or ␤ TCR chains. Downstream of the coding regions, IRES-puro (coding region: empty cassette or ␣ chain) and -neo (coding region: empty cassette, GFP, or ␤ chain; BD) cassettes were attached, respectively. Transduced T cells were expanded by weekly stimulation with ␣ CD3/CD28 Dynabeads (1 μ l per 10 6 cells; Invitrogen) and 40 -100 IU/ml rhIL-2, and were selected with 800 μ g/ml geneticin (Invitrogen) and 5 μ g/ml puromycin (Sigma-Aldrich) for 1 wk. Polyclonal CD4 + and CD8 + T cells transduced with ␣ and ␤ chains were sorted based on CD4 or CD8 expression and the level of TCR ␤ chain surface expression and were expanded in vitro using the rapid expansion protocol, as previously described ( 45 ) .
RT-PCR, fl ow-cytometry, and T cell assays. Expression of introduced ␣ and ␤ TCR chain was quantifi ed by fl ow cytometry using antibodies with specifi city for the ␤ chain, or by real-time PCR (TaqMan; Applied Biosystems) by using primers specifi c for the unique CDR3 region of the ␣ and ␤ chains. Standard 51 Cr-release ( 46 ), intracellular cytokine staining ( 47 ), ELISA ( 48 ) , and IFN-␥ ELISPOT assays ( 33 ) were performed as previously described. To assess the functional avidity of TCR-transduced cells, the EC50 (the concentration of peptide needed for half maximal cytokine secretion) was calculated and transformed to log EC50 ± SEM. To normalize gain of functional avidity for cells with ⌬ as compared with WT TCR chains, " log change in functional avidity " ( ⌬ log EC50 ) was calculated by subtracting log EC50 from cells transduced with ⌬ TCR chains, from log EC50 of cells transduced with WT TCR chains. To assess avidity (K D ) for TCR -pMHC binding, TCR-transduced cells were incubated with varying concentrations of tetramer for 45 min to achieve equilibrium. MFI of tetramer binding was determined by fl ow cytometry and plotted against the concentration of tetramer used for staining. The avidity (K D ) was derived from the slope by coreceptor, the relative improvement in functional avidity as a result of expressing ⌬ TCR chains did not exceed the relative improvement in CD4 + CD8 Ϫ T cells, suggesting that modifi ed interactions of the deglycosylated TCR chain with CD8 were likely not playing a major role in the observed change in functional avidity. Although our analysis of mutated TCRs that are CD8 dependent (mouse, v ␣ 13-D3/v ␤ 6; and human, v ␣ 21/ v ␤ 21) did not reveal that such TCRs become CD8 independent after transduction into CD4 + T cells (unpublished data) despite evidence of improved avidity if expressed in CD8 + T cells, this more likely refl ected the magnitude of change to achieve CD8 independence with these TCRs rather than a dependence on interaction with CD8.
Multiple mechanisms have been proposed to infl uence the fi ne tuning of T cell responsiveness, including modulation of glycosylation of the CD8 molecule ( 18 ) . Although regulation of N -glycosylation has been reported to aff ect T cell function ( 39, 40 ) , and T cells in distinct diff erentiation states exhibit diff erent levels of glycosylation (immature/mature and naive/memory) ( 15, 16 ) , there has been no direct evidence that altered N -glycosylation of TCR chains is a physiological mechanism to tune reactivity via modulating avidity. For example, activation of naive T cells could result in reduced N -glycosylation of TCR chains that could contribute to the improved functional avidity observed in antigen-experienced T cells. Diff erentially N -glycosylated TCR complexes have also been observed in mature CD4 as compared with CD8 T cells ( 41 ) , but the role of such diff erential N -glycosylation in defi ned T cell subsets has not yet been investigated.
In summary, we demonstrate that reduced N -glycosylation of TCR chains can improve functional avidity of TCR-transduced T cells in the absence and presence of the coreceptor CD8. We suggest that removal of specifi c N -glycosylation sites, in particular c-90 in the mouse TCR ␣ chain, allows a temperature-dependent change, such as improved TCR multimerization resulting in a diminished TCR -pMHC dissociation and, therefore, more effi cient T cell activation. Regardless of the individual mechanisms, this strategy can improve the avidity and potentially the effi cacy of TCRtransduced T cells and may therefore prove useful for current eff orts to redirect the immune system against cancer cells.
MATERIALS AND METHODS
Peptides, antibodies, multimeric complexes, and cytokines. Peptides p53 264-272 , MDM2 81-88 , and WT1 [126] [127] [128] [129] [130] [131] [132] [133] [134] , and the A/PR/8/34 infl uenza matrix protein M1 FluM1 58-66 were synthesized by SynPep. Anti -human -CD8 -FITC/PerCP/PCY5 and anti -human -v ␤ 21 -FITC (Beckman Coulter), and anti-mu ␤ /muv ␤ 3/muv ␤ 6TCR -PE/Pcy5 (BD) were commercially obtained. PE-labeled p53 264-272 , MDM2 81-88 , and WT1 126-134 tetramer HLA-A2 complexes were synthesized as previously described ( 42 ) . Capture/detector antibody pairs for use in IL-2 and IFN-␥ ELISA analysis were purchased from R & D Systems. IFN-␥ ELISPOT was performed with 1D1K and 7B61 capture and detection antibodies (Mabtech). IL-2 was obtained from Chiron, and ␣ CD3 (OKT3; Muromonab) was obtained from Ortho-Biotec. 
